Effectiveness and Safety of Radium-223 Dichloride

By Mª Alejandra Asensio Ruiz, Manuel Soria Soto, María Alejandra Asensio Ruiz

Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.

• Format: Paperback
• Language: English
• ISBN: B0CLFTBHCP
• ISBN13: 9786206581642
• Release Date: October 2023
• Publisher: Our Knowledge Publishing
• Length: 60 Pages
• Weight: 0.22 lbs.
• Dimensions: 0.1" x 6.0" x 9.0"